Modus Therapeutics AB
556669-2199ActiveSwedish biotech developing sevuparin for severe inflammatory diseases.
Oversikt
- Ukjent
- Ansatte
- Ukjent
- Omsetning
- 2004
- Grunnlagt
Nøkkelbeslutningstakere
John Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
+3 flere kontakter i Funnelfeedr
Beskrivelse
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions with high unmet needs. Their proprietary polysaccharide, sevuparin, is the core asset under development. Sevuparin is designed as a heparinoid that modifies inflammation while m...
Tagger
Nøkkelord
Teknologier i bruk
Bedriftsinformasjon
- Bransje
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE556669219901
Beslutningstakere
7 kontakter i FunnelfeedrJohn Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
Ellen Donnelly
Board Member
Claes Lindblad
CFO & Head of IR
Ellen K. Donnelly
Board Member
Lignende bedrifter
20 lignende bedrifter i FunnelfeedrSangair AB
3 ansatteDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
ZEALAND PHARMA A/S
0 ansatteDeveloping peptide medicines for metabolic health challenges globally.
Disruptive Pharma AB (publ)
5–9 ansatteSwedish biotech developing novel kidney disease therapies based on proprietary peptides.
Abera Bioscience AB
Developing next-generation nasal vaccines using modular OMV platform technology.
bioMérieux Sweden AB
20–49 ansatteWorld leader developing in vitro diagnostics for health and safety.
Utforsk mer
Spørsmål om Modus Therapeutics AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo